Stock comparison
Side-by-side financials for CRIS and MRNA. Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRNA is larger
Market cap data is available for the leading company in this comparison.
Market value leader
MRNA
Latest market capitalization comparison.
Revenue leader
MRNA
CRIS: $9.44M vs MRNA: $1.94B.
Profit leader
CRIS
CRIS: -$7.58M vs MRNA: -$2.82B.
Margin leader
CRIS
CRIS: -80.3% vs MRNA: -145.2% net margin.
| Metric | CRIS | MRNA |
|---|---|---|
| Market cap | - | $27.10 B |
| US-listed rank | - | #510 |
| Revenue (latest FY) | $9.44M | $1.94B |
| Net income (latest FY) | -$7.58M | -$2.82B |
| Net margin | -80.3% | -145.2% |
| P/E (trailing FY) | - | - |
| SEC filings | 1,000 | 1,447 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
In their latest fiscal years, CURIS INC reported $9.44M in revenue while Moderna, Inc. reported $1.94B.
Full pages: CURIS INC and Moderna, Inc., or browse the full rankings.